Toronto Man on Track to Become Canada’s First Person Cured of HIV
A 62-year-old Toronto man, known publicly only as the “Toronto patient,” is in sustained HIV remission and is poised to become the first Canadian cured of the virus. Doctors announced the landmark case in April 2026 at the Canadian Association of HIV Research Conference in Winnipeg. If his blood remains free of detectable HIV for the required monitoring period, he will join a tiny global group of people who have achieved what was once thought impossible.
The man was diagnosed with HIV in 1999 after presenting with stage 4 Burkitt lymphoma, an aggressive cancer that had already spread to his brain and lymph nodes. At the time, doctors did not expect him to survive more than six months. Antiretroviral therapy (ART) had only recently become available, offering the first real chance to suppress the virus and extend life. Under the care of infectious disease specialist Dr. Sharon Walmsley, he began ART and survived both the cancer and the HIV diagnosis. He went on to live with the virus for 27 years, keeping it under control with daily medication.
In 2021, a new crisis emerged. The patient developed acute myelogenous leukemia, a life-threatening blood cancer. Doctors determined he needed a bone marrow (stem cell) transplant. The procedure took place at University Health Network’s Princess Margaret Cancer Centre. Because he was living with HIV, the medical team searched internationally for a donor whose stem cells carried a rare genetic mutation known as CCR5-delta32.
This mutation disables a receptor on the surface of immune cells that most strains of HIV use to enter and infect them. People who inherit two copies of the mutation are naturally highly resistant to HIV. The mutation is found in roughly 1 percent of people of European descent. After searching global donor registries, the team identified a suitable match. The transplant replaced the patient’s immune system with these resistant cells.
The process is gruelling. Patients first undergo intensive conditioning with high-dose chemotherapy or radiation to destroy their existing bone marrow and immune system. Only then are the donor stem cells infused. The Toronto patient experienced serious complications afterward, including infections, kidney injury, a broken hip, and graft-versus-host disease. Despite these setbacks, the transplant succeeded in putting his leukemia into remission.
Researchers carefully tracked the HIV in his body. Over the years following the transplant, the amount of HIV DNA in his blood cells steadily declined. By the time he was clinically stable, sensitive laboratory tests could no longer detect viable virus or meaningful HIV-specific immune responses. In July 2025, with the agreement of his care team, he stopped taking antiretroviral therapy for the first time in nearly three decades.
As of April 2026, roughly nine to ten months later, his viral load remained undetectable on highly sensitive tests. Doctors describe the situation as “sustained remission.” If the virus stays undetectable for approximately two and a half years after stopping ART—into late 2027—he will meet the criteria used in previous cases and be considered cured.
The case was led by Dr. Sharon Walmsley, director of the immunodeficiency clinic at University Health Network and a professor at the University of Toronto, together with clinician-scientist Dr. Mario Ostrowski of St. Michael’s Hospital (Unity Health Toronto). Walmsley has cared for the patient since his original 1999 diagnosis. Reflecting on more than 40 years in the field, she has described watching HIV transform from a near-certain death sentence into a manageable condition and, in rare cases, a potentially curable one.
“I’ve been able to care and do research on this disease for over 40 years,” she said. “And I’ve watched it move from something that kills people in six months to a possible cure.”
The Toronto patient is approximately the 11th person worldwide reported to have achieved long-term HIV remission after a stem cell transplant from a CCR5-delta32 donor. The first was Timothy Ray Brown, known as the Berlin patient, who was cured in 2009 after treatment for leukemia. Subsequent cases have included the London patient, the Düsseldorf patient, the City of Hope patient, the Oslo patient and others. Each has provided researchers with valuable clues about how the virus can be eradicated from the body.
Despite the excitement, experts are careful to stress the severe limitations of this approach. Bone marrow transplants carry substantial risks, including a significant chance of death from complications. They are performed only when a patient already needs the procedure to treat life-threatening blood cancer. The treatment is extremely expensive, requires a rare genetic match, and is unavailable to the vast majority of the roughly 40 million people living with HIV globally. It is not a practical or scalable cure.
Researchers view these cases as proof of concept rather than a treatment model. They demonstrate that an HIV cure is biologically possible and help identify the mechanisms that clear the viral reservoir—the hidden pool of infected cells that allows the virus to rebound when medication is stopped. Insights from these patients are guiding efforts to develop safer strategies, including gene-editing techniques that could modify a patient’s own cells to resist HIV, therapeutic vaccines, and other approaches that do not require a full immune-system transplant.
For the Toronto patient, the primary focus remains his ongoing health monitoring. He has chosen to remain anonymous and continues under the care of the Toronto team. Doctors report that he is pleased to have contributed to scientific understanding of the disease, even if the daily experience of remission has not dramatically altered his routine.
The announcement marks a Canadian first and another incremental step in a decades-long scientific effort. While antiretroviral therapy has turned HIV into a chronic, manageable condition for millions, the search for a true cure continues. Cases like the Toronto patient’s show that the goal, once considered unreachable, is no longer theoretical. Each carefully documented success adds to the knowledge base that may one day make a widely accessible cure possible.
About The Author
